Skip to main content
Equibles

RA CAPITAL MANAGEMENT, L.P.

Position in TSHA — Taysha Gene Therapies, Inc.

CIK 1346824 BOSTON, MA
Back to TSHA Full portfolio

Position in TSHA

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$160,413,962
+$55,120,216 QoQ
Shares Held
23,555,648
0.0% QoQ
Ownership
7.23%
of shares outstanding
% of Portfolio
1.41%
of 13F equity value
Holder Rank
#2
of 208 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in TSHA Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

RA CAPITAL MANAGEMENT, L.P. holds $11,082,969,028 across 75 Biotechnology names. TSHA ranks #18 (1.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ASND
Ascendis Pharma A/S
 10,281,496 $2,742,280,613
2 PBLS
Parabilis Medicines, Inc.
 28,933,371 $791,906,364
3 RYTM
Rhythm Pharmaceuticals, Inc.
 6,666,837 $740,218,912
4 PCVX
Vaxcyte, Inc.
 11,474,599 $667,018,439
5 SION
Sionna Therapeutics, Inc.
 9,905,045 $435,722,929
6 TYRA
Tyra Biosciences, Inc.
 12,198,625 $389,624,082
7 EWTX
Edgewise Therapeutics, Inc.
 8,392,730 $340,996,619
8 NAMS
NewAmsterdam Pharma Co N.V.
 9,883,524 $330,779,298

All Filings in TSHA

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $160,413,962 23,555,648
2026-03-31 $105,293,746 23,555,648
2025-12-31 $129,556,064 23,555,648
2025-09-30 $77,026,968 23,555,648
2025-06-30 $54,413,546 23,555,648
2025-03-31 $15,112,779 10,872,503
2024-12-31 $18,809,430 10,872,503
2024-09-30 $21,853,731 10,872,503
2024-06-30 $24,354,406 10,872,503
2024-03-31 $31,204,083 10,872,503
2023-12-31 $32,696,330 18,472,503
2023-09-30 $58,373,109 18,472,503